PRGO - Perrigo Company PLC
Executive Summary
Perrigo Company plc is an Irish-domiciled, US-listed consumer self-care and consumer healthcare company that develops, manufactures, and distributes a broad portfolio of over-the-counter (OTC) medicines, nutritional products, and store-brand (private-label) consumer health goods across North America, Europe, and selected international markets. Within the US drug manufacturers - specialty and generic segment, Perrigo holds a leading position in private-label OTC analgesics, infant formula, and certain dermatology categories, supplying major retailers alongside its own branded lines.
The investment case rests on successful execution of the company's transformation programme, the deployment of divestiture proceeds to reduce leverage, and the delivery of an announced cost-savings initiative targeted at roughly $80 - 100 million of annual run-rate savings. The key near-term catalyst is the next set of quarterly results, with management having reaffirmed full-year 2026 guidance at the most recent reporting date; the principal risk is that disclosed supply-chain concentration in materials sourcing and ongoing regulatory oversight by US authorities (including USDA and EPA) create margin or compliance pressure that undermines the cost-savings narrative.
OPPORTUNISTIC BUY. Conviction Score: 59/100. The view would be upgraded on evidence of accelerating organic top-line growth, a clean quarter against maintained guidance, and visible deleveraging from divestiture proceeds, and would be downgraded on a guidance cut, a material adverse regulatory action, or a further deterioration in reported margins.
Thesis break: A cut to FY 2026 guidance, a material adverse regulatory action by USDA/EPA or the FDA, or a clear failure of the $80 - 100 million cost-savings programme to track towards its run-rate target would invalidate the thesis.
Business Model
Perrigo generates revenue primarily by manufacturing and selling consumer healthcare products - both its own branded lines and store-brand equivalents - through three reporting segments: Consumer Self-Care Products (which includes OTC medicines, nutritional supplements, vitamins, and minerals), Consumer Healthcare (which includes OTC analgesics such as acetaminophen/paracetamol and ibuprofen), and Consumer Products (which includes infant formula, allergy relief, and digestive health lines). Customers are predominantly large grocery, drug, mass-merchant, and club retailers who purchase store-brand products in high volume, together with wholesalers and distributors handling the branded portfolio.
The revenue mix is heavily skewed to North America, which the prior research data places at approximately 70% of group sales, with Europe contributing around 25% and the remainder generated from other international markets. Geographically concentrated revenue, combined with a manufacturing footprint that has historically centred on a small number of large US facilities, gives Perrigo scale efficiencies in its core categories but also exposes the group to single-site disruption risk, as evidenced by the previously disclosed FDA warning letter at the Allegan facility that constrained infant formula output until resolution in mid-2025.
The competitive moat sits in private-label manufacturing scale, deep retailer relationships, and FDA-registered production infrastructure that creates meaningful switching costs for store-brand customers. These advantages are partially offset by exposure to genericisation in OTC categories, retailer pricing power, and the sensitivity of input costs to commodity cycles in infant formula and dermatology. Reported results remain loss-making on a trailing twelve-month basis, with TTM EPS of ?12.50 and the P/E multiple unavailable because of the loss, which means the investment debate is currently framed around deleveraging, cost-out execution, and organic growth rather than earnings multiples.
Financial Snapshot
Recent Catalysts
[22 April 2026] - Perrigo Company plc issued a press release confirming that it would release its first-quarter 2026 financial results on 6 May 2026, with the announcement distributed via PR Newswire. Source: Perrigo Company plc press release (PR Newswire), as carried by Morningstar and Barchart.
[6 May 2026] - Perrigo reported its first-quarter 2026 financial results from continuing operations, announcing the figures on 6 May 2026 and reaffirming its full-year 2026 guidance alongside commentary on the Consumer Self-Care Products segment. Source: Perrigo Company plc press release (PR Newswire), reported under the headline "Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations".
[7 May 2026] - Coverage of the 6 May 2026 release noted that Perrigo had reaffirmed its FY 2026 earnings guidance, framed within the company's ongoing transformation plan and its previously announced cost-savings programme. Source: Daily Political, summarising the company press release of 6 May 2026.
[6 August 2025] - In its second-quarter 2025 results from continuing operations, management referenced the previously announced sale of the Dermacos business, providing context on the divestiture programme that is feeding into deleveraging. Source: Perrigo Company plc investor relations release ("Perrigo Reports Second Quarter 2025 Financial Results From Continuing Operations"), dated 6 August 2025.
[20 March 2026] - Zacks Research published an updated estimate ahead of Perrigo's second-quarter 2026 print, with a Zacks analyst team forecasting earnings of $0.55 per share for the quarter, against a prior-year comparable of $0.93 per share. Source: Zacks Research estimate note, as carried by Markets Daily and MarketBeat on 20 March 2026.
Thesis Evaluation
Bull Case (25% weight)
Operational delivery of the 3-S transformation plan lifts organic growth back into positive territory, the $80 - 100 million cost-savings programme is captured in full, and divestiture proceeds are used to materially reduce net debt while maintaining FY 2026 guidance. Under those conditions, a re-rating towards the 52-week high is plausible, and our bullish 12-month price target is $18.50.
Base Case (50% weight)
The cost-savings programme is delivered on schedule and divestiture proceeds are deployed to deleverage, but reported organic sales remain flat to modestly negative and TTM EPS stays close to breakeven, leaving the equity reliant on execution and balance-sheet improvement rather than earnings expansion. Our base-case 12-month price target is $15.75.
Bear Case (25% weight)
Declining organic sales compound, regulatory action by US authorities (USDA/EPA) creates incremental compliance or remediation costs, and the cost-savings programme underwhelms, leaving trailing losses intact. Under that path, the shares give back the post-divestiture re-rating and our bearish 12-month downside target is $10.50.
Key Risks
- Regulatory and compliance action: Disclosed oversight by US authorities including USDA and EPA, alongside the legacy of the Allegan FDA warning letter, creates a non-trivial probability of further enforcement or remediation that could pressure margins and volumes. Estimated probability: 30%. Impact: severe.
- Supply-chain concentration in materials sourcing: Filing-disclosed concentration in materials sourcing means a single-source disruption could weigh on gross margin and unit output in infant formula and dermatology. Estimated probability: 25%. Impact: moderate.
- Persistent negative organic sales: Continuing negative organic revenue growth, combined with a TTM EPS of ?12.50, would undermine management's transformation narrative and delay any return to a positive earnings base. Estimated probability: 45%. Impact: severe.
- Cost-savings programme underdelivery: The announced $80 - 100 million run-rate savings initiative is central to the bull case; partial capture or implementation costs above plan would compress the projected margin uplift. Estimated probability: 35%. Impact: moderate.
- Private-label pricing and retailer concentration: Perrigo's revenue is concentrated in US retailers' store-brand programmes, exposing margins to retailer-led price negotiations and shelf-space reassignments. Estimated probability: 40%. Impact: moderate.
- FX and European demand exposure: With European operations contributing roughly a quarter of group revenue, a weaker euro or sterling and weaker European consumer demand could weigh on reported results. Estimated probability: 30%. Impact: low.
Who Should Own It / Avoid It
Ideal for: patient, fundamentals-oriented investors with a minimum 12 - 18 month holding horizon, a tolerance for a loss-making, high-leverage name, and a willingness to underwrite balance-sheet repair and a multi-quarter cost-out programme rather than near-term earnings momentum. The position is best sized as a small-to-modest allocation within a diversified healthcare or special-situations sleeve, given the binary risk around regulatory and supply-chain outcomes.
Avoid if: investors require current-year positive earnings, cannot tolerate ongoing trailing losses, are unwilling to hold through further potential guidance revisions, or are looking for a stable dividend payer with low operational risk. Short-term traders, income-oriented investors, and those with mandates that exclude heavily indebted or loss-making issuers should not own this name.
Recommendation
OPPORTUNISTIC BUY - 59/100. We retain a constructive but cautious stance because the hard catalysts - completed divestiture, announced $80 - 100 million cost-savings programme, and reaffirmed FY 2026 guidance - outweigh soft organic-growth commentary and trailing losses, but disclosed supply-chain and regulatory risks materially temper the outlook. The call would be upgraded to a higher-conviction Buy on visible deleveraging from divestiture proceeds, a clean quarterly print against maintained guidance, or any acceleration in organic growth. The call would be downgraded to Hold or Sell on a guidance cut, a further adverse regulatory action, or evidence that the cost-savings programme is materially undershooting its run-rate target. At the current price of $16.18 the shares trade at or above our base-case target of $15.75: the base case is fully priced, existing holders should consider trimming, and new positions are not advised above $12.25.
The probability-weighted value across our three scenarios is $15.13, 6% below the current price of $16.18 - the market is currently pricing the shares ahead of our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below $12.25 - below this level the upside to the base-case target ($15.75) is at least 2x the downside to the bear case ($10.50), the minimum risk/reward we require before committing new capital.
between $12.25 and $15.75 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above $15.75 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 25%.
if A cut to FY 2026 guidance, a material adverse regulatory action by USDA/EPA or the FDA, or a clear failure of the $80 - 100 million cost-savings programme to track towards its run-rate target would invalidate the thesis, regardless of price - the bear target of $10.50 is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 59/100. Trend versus prior report: Initiation.
| Report date | Conviction |
|---|---|
| 2026-10-04 | 59 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: public news flow including company press releases distributed via PR Newswire, regulatory and financial news wires, third-party analyst estimate notes, and mainstream financial data providers covering the company's quarterly reporting cycle and transformation updates.
Primary source types: SEC and equivalent regulatory filings, company press releases, company investor relations materials (including quarterly results announcements and earnings release dates), and third-party research notes carrying analyst earnings estimates; coverage aggregators and financial data platforms were used for cross-referencing only and not as the source of any factual claim.
Key sources
- Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations - Feb 26, 2026
- Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations
- Perrigo Company plc (PRGO) Stock Price, News, Quote & History - Yahoo Finance
- Perrigo InvestorRoom - Press Releases
- Perrigo (NYSE:PRGO) - Stock Analysis - Simply Wall St
- Perrigo Company (PRGO) Stock Price & Overview
- Perrigo (PRGO) Reaffirms 2026 Guidance, Is The Three S Plan Priced In? - Simply Wall St News
- View Filing Data
- perrigo-2026facilityxame
- Perrigo (PRGO) Acquisition Rumors Surface
Analysis generated 2026-10-04. Market data as of 2026-11-12.